Volume 41, Issue 3, Pages 474-481 (September 2004) Peginterferon alfa-2b plus ribavirin for naïve patients with genotype 1 chronic hepatitis C: a randomized controlled trial  Savino Bruno, Calogero Cammà, Vito Di Marco, Mariagrazia Rumi, Maria Vinci, Mario Camozzi, Chiara Rebucci, Danilo Di Bona, Massimo Colombo, Antonio Craxì, Mario U. Mondelli, Giovanbattista Pinzello  Journal of Hepatology  Volume 41, Issue 3, Pages 474-481 (September 2004) DOI: 10.1016/j.jhep.2004.05.012 Copyright © 2004 European Association for the Study of the Liver Terms and Conditions

Fig. 1 Flow chart of the selection process of the two groups of patients. The distribution per center of patients included in the trial was as follows: San Giuseppe Hospital (Milano) 11 patients, San Paolo Hospital (Milano) 70 patients, University of Messina Medical Center (Messina) 8 patients, Niguarda Hospital (Milano) 49 patients, University of Palermo Medical Center (Palermo) 82 patients, IRCCS San Matteo Hospital (Pavia) 31 patients, IRCCS Spallanzani (Rome) 10 patients, IRCCS Ospedale Maggiore (Milano) 50 patients. Journal of Hepatology 2004 41, 474-481DOI: (10.1016/j.jhep.2004.05.012) Copyright © 2004 European Association for the Study of the Liver Terms and Conditions

Fig. 2 Sustained virologic response rate of the 163 patients treated with peginterferon alfa-2b plus ribavirin as a function of fibrosis by Ishak score, at baseline liver biopsy. Journal of Hepatology 2004 41, 474-481DOI: (10.1016/j.jhep.2004.05.012) Copyright © 2004 European Association for the Study of the Liver Terms and Conditions

Fig. 3 Box plots of weighted doses of PEG-IFN (A), and Ribavirin (B) according to sustained virological responses (SVR). Box plots include the middle 50% of the data. The horizontal bars inside the box represent medians. The upper and lower ends of the boxes (hinges) represent the approximate upper and lower quartiles of the data distribution. Extreme data are connected to the ends of the boxes by vertical bars. The diamonds include the middle 68% of the data (mean±1 standard deviation). [This figure appears in colour on the web.] Journal of Hepatology 2004 41, 474-481DOI: (10.1016/j.jhep.2004.05.012) Copyright © 2004 European Association for the Study of the Liver Terms and Conditions

Fig. 4 Cumulative rate of discontinuation of therapy in patients treated with peginterferon-α2b plus ribavirin (PEG-IFN) and in patients treated with interferon-α-2b and ribavirin (IFN). The difference was statistically significant (P=0.01, by log rank test). Journal of Hepatology 2004 41, 474-481DOI: (10.1016/j.jhep.2004.05.012) Copyright © 2004 European Association for the Study of the Liver Terms and Conditions